Santhera Pharmaceuticals Expands Reach with Exclusive Distribution Agreement in Türkiye

Pratteln, Switzerland, August 13, 2025 — Santhera Pharmaceuticals Holding AG, a leading biotechnology company specializing in neuromuscular and metabolic diseases, has announced a strategic move to expand its market presence in Türkiye. The company has signed an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN), a prominent player in the Turkish specialty pharmaceuticals market, for the distribution and promotion of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged four years and older.

This partnership marks a significant milestone for Santhera as it seeks to enhance its global footprint. The agreement stipulates that GEN will commence supply and sales of AGAMREE® in the first half of 2026, initially on a named patient basis, transitioning to commercial sales thereafter. This phased approach allows for a tailored introduction of the drug to the Turkish market, ensuring that patients receive the necessary treatment while establishing a robust commercial framework.

Santhera has received a small upfront payment as part of the agreement, with provisions for an ongoing percentage of net sales, aligning the interests of both parties towards the successful commercialization of AGAMREE® in Türkiye. Dario Eklund, Chief Executive Officer of Santhera, expressed confidence in the partnership, stating, “As leaders in the Turkish specialty pharmaceuticals market, GEN were a natural choice for Santhera as we looked for a high-quality partner to bring AGAMREE® to patients in Türkiye.”

The strategic alliance with GEN not only underscores Santhera’s commitment to expanding access to its innovative therapies but also highlights the company’s proactive approach in navigating complex regulatory landscapes and establishing strong local partnerships. With a market capitalization of CHF 174.87 million and a close price of CHF 12.94 as of August 11, 2025, Santhera continues to demonstrate resilience and growth potential in the competitive biotechnology sector.

As Santhera prepares for the launch of AGAMREE® in Türkiye, stakeholders are optimistic about the potential impact on the treatment landscape for DMD patients. The company’s focus on neuromuscular and metabolic diseases positions it well to capitalize on emerging opportunities in global markets, reinforcing its status as a key player in the biotechnology industry.

This development is a testament to Santhera’s strategic vision and its ability to forge meaningful collaborations that drive forward its mission to improve the lives of patients with rare diseases. As the company looks ahead, the Türkiye market represents a promising frontier for AGAMREE® and other innovative therapies in Santhera’s pipeline.